Synthesis and Biological Evaluation of Novel Anthranilamide Derivatives as Anticancer Agents
News Oct 23, 2013
A new series of anthranilamide derivatives were synthesized and evaluated for their antiproliferative activities against human colon carcinoma cell lines (HCT 116) and human breast adenocarcinoma cell lines (MDA-MB-231) in vitro. The bioassay results indicated that compounds 7a-7d, 11a, and 11b with flexible linkers showed promising antiproliferative activity against both cell lines. Among the compounds synthesized, 7c showed the most significant antiproliferative activity. Flow cytometric analysis indicated that 7c inhibited HCT 116 and MDA-MB-231 cell growth by inducing apoptosis in a dose-dependent manner and suppressed HCT 116 cell proliferation by G1 and S phase arrest. Compound 7c may serve as a lead candidate in the development of novel anticancer agents.
This article was published online in Drug Discoveries and Therapeutics and is free to access.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Construction of State-of-the-Art Flow Chemistry Facility CommencesNews
Construction has commenced on a new $8 million Centre for Industrial Flow Chemistry at the CSIRO’s Normanby Rd Clayton site. The purpose-built, 410m2 state-of-the-art facility will provide local manufacturers access to CSIRO’s flow chemistry technology.
Yuriy Roman: A Chemical Engineer Pursuing Renewable EnergyNews
MIT professor, Yuriy Roman, devises new ways to generate useful chemicals and fuels from renewable resources.READ MORE